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ABSTRACT
Investigating Biosynthetic Steps of an Angucycline Antifungal
by
S. Gabrielle Gladstone, Master of Science
Utah State University, 2016

Major Professor: Jixun Zhan
Department: Biological Engineering
From the bacterium Streptomyces sp. SCC-2136 (ATCC 55186), two angucycline natural products are produced, designated Sch 47554 and Sch 47555. These compounds are
produced through a type II polyketide biosynthetic pathway. The early biosynthetic steps
to these molecules were confirmed. These include the minimal polyketide synthase (PKS),
the C-9 ketoreductase, the first-ring aromatase, the subsequent ring cyclase, and two oxygenases. Also confirmed were the biosynthetic genes responsible for production of the first
amicetose moiety, as well as the glycosyltransferase that creates a C -glycosidic bond between the angucyclic scaffold and the amicetose moiety. In confirming these pathways, two
new natural products were produced: GG31, an amitosylated rabelomycin, and GG53, rabelomycin hydroxylated at C-12b. Future work will be to understand the late biosynthetic
steps and generate new angucyclines through combinatorial biosynthesis.
(64 pages)
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PUBLIC ABSTRACT
Investigating Biosynthetic Steps of an Angucycline Antifungal
S. Gabrielle Gladstone
The species of bacterium Streptomyces sp. SCC-2136 which has the American Type
Culture Collection index 55186 naturally produces two chemical compounds, labeled Sch
47554 and Sch 47555. These compounds were previously reported to posess antifungal
activity. This thesis sets out to confirm the mechanism by which the bacterium produces
these compounds; specifically which genes are responsible for producing the enzymes that
make and shape the molecules.
The genes and enzymes that were characterized are the minimal polyketide synthase,
the ketoreductase that specifically acts on the ninth carbon, the first-ring aromatase, the
subsequent ring cyclase, and two oxygenases. Also elucidated were the genes responsible
for production of the first sugar (called amicetose) in the chain of two sugars attached to
carbon 9 as well as the glycosyltransferase enzyme that attaches this sugar to the rest of
the molecule.
In confirming these pathways, two new compounds were produced: GG31, which has
a base structure of the antibiotic rabelomycin but is attached at carbon 9 to a molecule of
the deoxysugar amicetose; and GG53 which has the base structure of rabelomycin but with
a hydroxyl group at carbon 12b. Future work will be to understand the later biosynthetic
steps and generate new related molecules through combinatorial biosynthesis.

v

Maria Montessori once said, ”The preparations for life are indirect”. This is certainly true.
This thesis is dedicated to my parents, Melissa and Russell Gladstone; to Andrew Tori
Hamblin; to Kandy Napan-Hsieh; and to Aerin Richardson.
Wasn’t this a wild ride.
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CHAPTER 1
Introduction
There is a joke about the history of medicine that appeared in the now-discontinued
Western Journal of Medicine. It is presented as a table:
The History of Medicine
2001 BC

Here, eat this root.

1000 AD

That root is heathen. Here, say this prayer.

1850 AD

That prayer is superstition. Here, drink this potion.

1920 AD

That potion is snake oil. Here, swallow this pill.

1945 AD

That pill is ineffective. Here, take this penicillin.

1955 AD

Oops, bug mutated. Here, take this tetracycline.

1960-1999 AD

39 more “oops”...Here, take this more powerful antibiotic.

2000 AD

The bugs have won! Here, eat this root.

Natural products, a term which refers to any compound made by a living organism,
are often responsible for why “this root” is still theoretically a viable medicinal treatment.
Natural products have been studied in organic chemistry since at least 1891, when Albrecht
Kossel classified them into two categories: primary and secondary metabolites [21]. Primary metabolites are vital for the survival of the organism, e.g. structural or nutritional.
Conversely, secondary metabolites are not vital to the immediate survival of the living organism, but provide a competitive advantage. Usually this is accomplished by affecting
some other organism- for example to deter predators, control parasites, or in the case of
antimicrobials, to kill off competition.
Antimicrobial natural products have a variety of structures, and are often classified
based on the structural properties they possess. The first natural product with antibacterial
activity to be discovered was penicillin, discovered by Alexander Fleming in 1929 [21], and
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the category of antibacterial agents that has grown from this discovery is called β-lactam
drugs, because of the 4-membered lactam ring that is present in each structure. Other
categories of include macrolactones, because each has a lactone ring containing more than
8 carbons; tetracyclines, which contain four rings; and angucyclines, which are similar in
structure to tetracyclines, but the four rings are not attached linearly, but at an angle.
Naturally occurring macrolactones, tetracyclines, and angucyclines are all secondary
natural products from the genus Streptomyces, a genus of soil- and marine-dwelling Grampositive bacteria. Because of their complex secondary metabolism, various Streptomyces
species are responsible for over two-thirds of naturally occurring antibiotics [20], including
many members of the families listed above.

Fig. 1.1: Structures of angucycline compounds Sch 47554 (1), Sch 47555 (2), aquayamycin
(3), and urdamycin A (4)
This thesis details the pursuit of understanding the biosynthetic pathway of one specific
pair of natural products, Sch 47554 (1) and Sch 47555 (2), which belong to the angucycline
family of compounds. Angucyclines are part of a larger classification of natural products
that are built by type II polyketide synthases. These two molecules, which are identical except for the second sugar in the disaccharide moiety on ring D, were discovered in 1993 from
Streptomyces sp. SCC-2136. They possess an aglycon very similar to that of aquayamycin

3
(3) and the synthetic compound SS-228Y5, except for the differing sugars. Biologically,
(1) and (2) possess moderate antifungal activity and are also weak inhibitors of tyrosine
hydroxylase [6], an integral enzyme in the conversion of tyrosine into neurotransmitters. Despite their potential as medicines, the biosynthetic pathway of these compounds remained
unknown. In 2006, a group from South Korea sequenced the gene cluster of Streptomyces
sp. SCC-2136, and used BLAST searching to find homologous DNA sequences. Results
showed that many genes were similar to those involved in the synthesis of urdamycin A (4)
by Streptomyces fradiae, but some enzymes had homologies to other products’ gene clusters [5]. The genes putatively involved in the biosynthesis of (1) and (2) were annotated but
not functionally characterized, which has hampered the understanding of the biosynthetic
process of these antifungal molecules.
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CHAPTER 2
Literature Review
The study of natural product biosynthesis gives inspiration toward engineering new
“unnatural” natural products, because a molecule’s novel functionality might suggest new
pathways or a way to improve an existing molecule. Of the natural products available,
the most intriguing are the polyketides, which have been isolated from bacteria, fungi, and
plants [44]. These molecules are assembled by three types of polyketide synthases (PKSs):
type I, type II and type III. All three do similar actions: synthesis of natural products via
chaining together molecules of acetyl-coenzyme A, and then tailoring this chain into various
conformations. The mechanisms, though, are the differences between the three types.

2.1

Type I and Type III PKS
Type I PKSs are large, multimodular enzymes with covalently fused domains that

perform individual catalytic activities [45]. The essential domains are the ketosynthase (KS)
domain, the acyl transferase (AT) domain, and the acyl carrier protein (ACP). These three
domains catalyze the elongation of the polyketide chain. Other domains are ketoreductase
(KR), dehydratase (DH), enoyl reductase (ER) and methyltransferase (MT). Often these
are present in the type I PKSs to modify the chain, but there are occurrences of the tailoring
steps taking place via enzymes separate from the large PKS.
One example of post-PKS tailoring occurs in the biosynthesis of the anticholesterol
natural product herboxidiene, first discovered from Streptomyces chromofuscus. There are
seven genes in the gene cluster for herboxidiene; the three that code for the PKS are
hypothesized to be herB, herC and herD. It is predicted that HerB contains a loading
module and three elongation modules; HerC consists of three elongation modules, and HerD
has one elongation module. This allows the electrophilic attack of the vinyl adjacent to the
first carbonyl, causing the separation of the nascent chain. The molecule is then available for
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Fig. 2.1: The proposed organization of the herboxidiene biosynthetic gene cluster
modification by domains HerE, HerF, HerG, which are an epoxidase, a methyl transferase,
and hydroxylase, respectively [36]. Recently, HerF was confirmed via knockout experiments
and in vitro reactions to catalyze the formation of the methoxy at C-25, depicted in Figure
2.1.
In contrast to noniterative PKSs, some type I PKSs are iterative (iPKS), meaning
that their architecture involves fewer domains that get repeatedly used [7]. Among iPKSs
are highly reducing PKSs (hrPKS), partially reducing PKSs (prPKSs) and nonreducing
PKSs (nrPKSs). The biosynthesis of macrolactone natural products like radicicol involves
collaborative actions of a hrPKS and an nrPKS. The hrPKS (consisting of KS, AT, ACP,
KR, DH, and ER domains) synthesizes a reduced polyketide chain, which is transferred to
the partner nrPKS by a starter unit/acyl-carrier protein transacylase (SAT) domain. This
nrPKS elongates the chain to a certain length, utilizes the product template (PT) domain
to form an aromatic ring by specific aldol condensation, and then the thioesterase domain
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closes the macrolactone ring [42].
Type III PKSs are different from type I PKSs. The enzyme complex is made up of two
small homogeneous enzymes, each with a single active site. The homodimer uses the two
active sites iteratively to catalyze the Claisen condensations of one or more extender units
onto a starter substrate [16], the species of substrate depending on the type of organism.
Most plant type III PKSs use free acyl-CoA as a starter unit, but bacteria and fungi use
an acyl-ACP. As is to be expected, the final product will differ depending on the number
and type of extender substrates used, as well as the cyclization pattern [43].

2.2

Type II PKS
Type II PKSs have similar intermediate products as type I and type III (a long polyke-

tide chain), but the mechanism by which they create this chain this is different. A type
II PKS cluster is made of a series of discrete enzymes that form multi-enzyme complexes
to catalyze the synthesis of polyketide chains. Additionally, depending on the substrates
required, some components of type II PKS are interchangeable across species. Thus, the
minimal PKS of a type II PKS gene cluster is comprised of an ACP to bring malonyl
CoA extenders to the growing chain; a KS to attach the extender, and a chain length factor (CLF) to control the length of the chain. In a system where these three enzymes are
all the only type II PKS components that are expressed, the generated polyketide chain
will spontaneously fold into more stable products. In the absence of tailoring enzymes
like aromatases (AROs) and cyclases (CYCs), a newly-formed decaketide (made from one
acetyl-CoA and nine malonyl-CoAs) will spontaneously fold into one SEK15 (5); and an
octaketide chain will likewise fold into SEK4 (7), as seen in Figure 2.2. Hence the minimal
PKSs from different species are comparable. When expressed in Streptomyces, the genes of
various minimal PKS will all generate spontaneous products determined by the length of
the original polyketide chain.
With the addition of a KR in the expression vector, different sets of spontaneous
products are observed, again depending on the length of the chain. This is because the
reduction of one specific ketone group, usually the one attached to C-9, is enough to make the
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Fig. 2.2: The polyketide chain folds spontaneously into different, but predictable, structures
depending on how many malonyl CoA molecules they contain, and whether or not Carbon
9 is reduced
spontaneous cyclization include a heterocyclic pyran ring in the scaffold. A decaketide chain
reduced at C-9 folds into RM20b/c (6); the C-9 reduced octaketide chain becomes mutacin
(8). Both the minimal PKS and the KR functionalities are conserved across different type
II PKS clusters, in that it is possible to combine the minimal PKS from one gene cluster
(e.g. oxytetracycline) and the KR from a different cluster (e.g. tetracenomycin [13, 32])
and arrive at the same products (again, see Figure 2.2).
This conservation is not necessarily the case for CYCs. This type of enzyme catalyzes
the formation of the subsequent rings. Aromatases are also included in this family, since
AROs are simply CYCs that are specialized for the first ring. The proposed mechanism
is formation of an enol via nucleophilic attack of a carbonyl to the alpha carbon on the
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other side of the chain. The enol then collapses, resulting in the first-ring cyclization
[23]. Subsequent ring formations follow a similar mechanism. However, in heterologous
expression with other PKS enzymes, it was observed that some CYCs seem to have a
minimal requirement for the length of the polyketide chain. This is logical: if a CYC is
geared to catalyze a fourth ring closure but is presented with a chain from which only three
rings can form, that particular CYC will not work. Experiments also suggested that certain
CYCs cannot work on polyketide chains that have not been reduced at specific carbons [29],
especially if the enzyme is an ARO. This is because most aromatases are specialized to the
first ring of the scaffold. Typically, the ARO will catalyze the formation of the first ring,
and the CYCs that follow will direct the formation of the second ring and so on. But if
the chain is reduced at a specific carbon, the steric conformation may be incorrect for the
catalytic mechanism of the ARO. The result is that the enzyme has a different level of
activity towards the reduced chain, and the end product may be different.

Fig. 2.3: Biosynthesis of oxytetracycline and reported shunt products
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This is apparent in the biosynthetic pathway of 12, oxytetracycline (Figure 2.3), which
contains OxyABCD, OxyJ, and OxyK, as the minimal PKS, C-9 KR, and ARO respectively
[32]. Following the aromatase is the CYC OxyN, which cyclizes the second and third rings.
The final ring forms when the C-1 carbonyl attacks C-18 as the molecule breaks the thioester
bond and separates from the enzyme [32].
Unique to tetracycline compounds, however, is the amidotransferase gene from S.
rimosus as oxyD and in Streptomyces sp. SF2575 as ssfD, as evidenced by the nitrogencontaining compounds WJ85 (9) and WJ35 (10) that spontaneously form when only oxyABCD
and oxyABCDJ or ssfABCD and ssfABCDJ are expressed, respectively [32, 33]. Following
amination and ketoreduction, several different tailoring enzymes work to decorate the newly
formed pretetramid. OxyF introduces the methyl group at C-6; OxyE and OxyL cooperate to create the double-hydroxylation between the third and fourth ring. OxyQ catalyzes
the reductive amination at C-2, which is then followed by the methylation of the nitrogen
via OxyT to make a tertiary amine. The resulting molecule is anhydrotetracycline (11).
A precursor to 12, 11 is the first of the intermediates in the tetracycline family to be a
functional antibiotic, due to the groups in position on the fourth ring.

2.3

Angucycline Compounds
Angucycline natural products have been extensively studied since at least 1959, when

scientists in the Miyago prefecture of Japan described ayamycin, a compound from Streptomyces flaveoulus ATCC 13118, although the structure was never elucidated. Four years
later, scientists in the Aomori prefecture cultured a different Streptomyces strain and isolated aquayamycin (3). Growth inhibition assays were conducted, and it was found that
3 inhibited Gram-positive bacteria, with the exception of mycobacteria [20]. The Aomori
group also hypothesized an approximate molecular formula based on NMR and IR spectra, but the structure was unknown until 1970 when it was elucidated as a derivative of
benzene[α]-anthracene with one C-linked deoxysugar [30]. Fifteen years later, Dr. Jürgen
Rohr discovered urdamycin A (4) [11], one of the most important angucycline natural products. Extensive studies have been done on 4, and it is a standard to which other angucycline
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compounds are compared.
The structure and biosynthesis pathways of several angucycline products have been
deciphered, but most are yet to be determined. Like other type II PKS pathways, those that
produce angucyclines begin with a minimal PKS, and then continue with the aforementioned
tailoring enzymes. The angular ring is formed by a specific type of CYC that works to close
the fourth ring in the benz-α position instead of as an anthracene as with chromomycin
[35], or an octahydrotetracene, as with oxytetracycline. This differently shaped scaffold
allows for new patterns of functional groups, created by glycosynthases, glycosyltransferases,
oxidoreductases and methyltransferases.

2.3.1

Angular Hydroxyls

The hydroxyl groups at the angle of the α ring are an example of the unique functionality. It has been hypothesized that the enzymes responsible for these oxidations catalyze
a Baeyer-Villager rearrangement [30], and the deletion of such oxygenases result in spontaneous formation of products like rabelomycin [11]. It is proposed that the oxidation of
C-4a and C-12b is catalyzed in each gene cluster by the same enzyme that oxidizes the
hydroxyl at C-12 into a carbonyl. Many pathways have confirmed the enzymes responsible
for this type of oxidation in different compounds; namely LanE, PgaE, CabE catalyze both
the oxidation at C-12 and C-12b. Other related enzymes likewise do the oxidation at C-12,
but actually perform a dehydration reaction at C-4a/C-12b, resulting in an unsaturated
angular bond; essentially the opposite of the previously described double-oxidizers.
Other pathways, like that of 4, split this oxygenation up into two enzymes: one for
C-12, and one for C-12b. In the Urd pathway, these are UrdE and UrdM respectively it
was once thought that UrdE was like the dual-functioning oxygenases as described above,
especially when compared with LanE (to which it shares a 73% amino acid identity) and
PgaE (77% identity). However, when UrdM was inactivated, all urdamycin A production
was eliminated, and instead the shunt products rabelomycin and urdamycin L were formed
(see Figure 2.4) [19].
It would seem that if UrdE is present in the reaction system, UrdE oxidizes C-12 to
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a carbonyl, and UrdM does the above two-step oxidation, showing that the two enzymes
do indeed work together. Curiously, though, further experiments showed that when the
reduction domain of UrdM is isolated separately, the reaction proceeds in the same way,
as described in Figure 2.5 [?]. This is also supported by the notion that urdamycin L, the
shunt product described in Figure 2.4, is made in very small amounts (less than 1 mg per
liter) [35]

2.3.2

Glycosylation

In addition to oxidization, another category of angucyclines, and indeed many natural
products, is those natural products that contain sugar moieties, including rebeccamycin,
an indolocarbazole antitumor candidate [4]; and puerarin, an isoflavone antioxidant [24]
(Figure 2.6) as well as the aforementioned 4.
For angucyclines, the glycoside moieties tend to be deoxysugars, which are derived from
glucose-1-phosphate, which itself is synthesized directly from glucose either by anomeric
phosphorylation or derived via phosphoglucomutase [25,40] from glucose-6-phosphate. Once
the glucose-1-phosphate has been activated via coupling to a nucleoside phosphate (usually
thymidine diphosphate, or TDP), the pathway continues and modifies the sugar. This is
accomplished by a specific sequence of reductases, dehydratases, and epimerases that are
unique to each sugar, although the pathways to build similar sugars are very homologous
across different species of Actinobacteria. Figure 2.7 depicts this phenomenon, as several
deoxysugars are formed from glucose-1-phosphate, via dehydratases, epimerases, ketoreductases, and methyltransferases. It is important to note that most of these sugars are made
by different species of bacteria; although a few sugars show up frequently in different natural products. Additionally, there have been successful expressions of sugar plasmids with
heterologous sugar genes to create both the expected and novel deoxysugars [1].
Once the activated deoxysugars have been synthesized, they are now able to be coupled to the polyketide scaffold by one or more glycosyltransferases (GTFs). The reaction
catalyzed by GTFs is simply a redox reaction between a sugar donor and a sugar acceptor.
For angucyclines and other type II PKS natural products, the sugar donor is the activated
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deoxysugar, and the acceptor is the aromatic polyketide itself.
In the case of urdamycin, there are four glycosyltransferases. Two that act upon the
scaffold: UrdGT2, which catalyzes the C-C link between C-9 of the scaffold and the aliphatic
carbon of a D-olivose moiety [9, 19, 25]; and UrdGT1a, responsible for the catalyst of an
O-linked L-rhodinose at C-12b. UrdGT1c extends the sugar chain at C-9 by attaching an
L-rhodinose via an α(1-3) O-linkage to the D-olivose mentioned above; and finally UrdGT1b
completes the trisaccharide chain with the α(1-4) O-linkage of D-olivose to the L-rhodinose
(2.8).
Yet because individual enzymes are potentially very specific to the aglycan sugar acceptor, and the individual saccharide sugar donor, it was assumed that enzymes like UrdGT2
and LanGT2 (a similar angucycline with O-linked sugars) were specific to their respective final products and related intermediates. On the contrary, the enzyme ElmGT was
discovered as being structurally homologous to each of the glycosyltransferases from the
urdamycin and landomycin pathways [41], that was able to catalyze “at least eleven different sugars” [34] onto its tetracenomycin derivatives. This provides evidence that further
novel natural products might be made by simply switching glycosyltransferases between
Streptomyces species, resulting in glycodiversification.
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Fig. 2.4: Oxidoreductase UrdM catalyzes a 2-step reaction at carbon 12b in the pathway
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Fig. 2.5: Catalysis of 12 and 12b oxidation by UrdE and UrdMred, the reducing domain of
UrdM

Fig. 2.6: Rebeccamycin and puerarin, two of many natural products containing sugar moieties
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Fig. 2.7: Deoxysugars that can be synthesized from common intermediates

Fig. 2.8: The four urdamycin glycosyltransferases
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CHAPTER 3
Experimental Methods

3.1

Extraction of Genomic DNA
Once a suitable culture of Streptomyces sp. SCC 2136 ATCC 55186 was established on

solid YM media, a single colony was selected into liquid YM media. After approximately
12 hours of growth at 250 RPM at 28 o C, the genomic DNA was extracted using the
phenol-chloroform technique [46], and was purified by washing with 70% ethanol.

3.2

Polymerase Chain Reaction and Amplification of Genes
Primers for each gene of interest were designed to include restriction sites to facilitate

cloning and ligation procedures. The sequences of these primers are presented as Table 3.1
below. The primers were ordered from Sigma-Aldrich and reconstituted with TE buffer
to the approximate concentration of 100 ng/mL. The PCR was then performed for the
genes using the recipe printed in table 3.2 and Phusion DNA polymerase (ThermoFisher).
The agarose gel purified PCR product was ligated into the pJET 1.2 cloning vector (ThermoFisher) using T4 DNA ligase (New England Biolabs) and transformed into E. coli XL1
Blue competent cells. After an overnight culture at 37 o C on solid LB media supplemented
with carbenicillin (50 µg/mL), several colonies were picked into liquid LB with carbenicillin,
grown at 37 o C for an additional 8-10 hours, and the plasmids extracted from each colony
using alkaline lysis and column purification (ThermoFisher Gene-JET). A small amount
of each plasmid sample was digested using the corresponding restriction endonucleases in
order to verify the size of the inserted gene, as compared with the Gene Ruler 1kb Plus
DNA ladder (ThermoFisher). When a sample had been identified as likely correct, high
concentrations of the plasmid were sent out for sequencing (Eton Biosciences) in order to
ensure that the gene was correct and free of mutations.
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Table 3.1: Sequences of primers used for plasmid construction
Genes

5’Primer

Restriction Enzymes

oxyAoxyB

5’AATTAATTAAGGAGGAGCCCATATGTCCAAGATCCATGACGC3’

PacINheI

5’AAGCTAGC TCAGTCCCGGCCGCTGACCA3’

oxyC

5’AAACTAGT GGAGGAGCCCATATGACCCTGCTCACCCTCTC3’

SpeI/NheI

5’AAGCTAGC TCACTTGTCCCGCGCGGCGC3’

oxyD

5’AAACTAGT GGAGGAGCCCATATGTGCGGAATCGCCGGCTG3’

SpeI/NheI

5’AAGCTAGC TCATAGCTCCAGGCTGACGC3’

schP3

5’AAACTAGT GGAGGAGCCCATATGGAGATCCTCGACGGTCT3’

SpeI/NheI

5’AAGCTAGC TCAGCGCAGCAGCGTGCCGC3’

schP4

5’AAACTAGT GGAGGAGCCCATATGACCGTCCGTGAGGTCGA3’

SpeI/NheI

5’AAGCTAGC TCAGCGCCGCGCTTCGGCGT3’

schP5

5’AAACTAGT GGAGGAGCCCATATGACGACTGCCACGTCCGG3’

SpeI/NheI

5’AAGCTAGC TCAGAAATTGCCGAGGCCGC3’

schP6schP7schP8

5’AATTAATTAAGGAGGAGCCACCACTGGACCGCACTGTGA3’

PacI/NheI

5’AAGCTAGC TCAGCTGGACCGGACGGGCA3’

schP9

5’AAACTAGT GGAGGAGCCCATATGCACAGCACGCTGATCGT3’

SpeI/NheI

5’AAGCTAGC TCACAGTGCGGTCCAGTGGT3’

schP10

5’AAACTAGT GGAGGAGCCCATATGGATGCTTCGGTCATAGT3’

SpeI/NheI

5’AAGCTAGC TCAGGACTTCGGGCCCCGCG3’

3.3

Creating Plasmids for Heterologous Expression
Each gene or block of genes was cloned as described above, then ligated together via

cutting with the appropriate restriction endonuclease (New England Biolabs) and inserting
the genes. Often, genes were ligated using compatible, but non-identical sticky ends (e.g.,
the family of NheI, SpeI, XbaI, and AvrII) that cannot be re-cut with the same enzymes.
This allowed us to form large fragments of DNA that could be easily ligated into the
expression vector pRM5 between the PacI and NheI restriction sites.
Once the pRM5-derived plasmid had been purified and its concentration measured,
the plasmid was introduced into Streptomyces lividans K4 protoplasts via polyethlylene
glycol (PEG) aided transformation. After allowing the transformed protoplasts to recover
on solid R5 media for 12-16 hours at 28 o C, an antibiotic was overlaid to select for positive
transformants: 50 µg/mL thiostrepton in R5 media with 0.8% agar. Positive transformants
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Table 3.2: General PCR mixture
Sterilized water

14.2 µL

High fidelity buffer

4 µL

DMSO

0.6 µL

100 mmol dNTP

0.4 µL

3’ primer

0.2 µL

5’ prime

0.2 µL

Genomic DNA template

0.2 µL

Phusion DNA polymerase

0.2 µL

Total Volume

20 µL

were identified after 4-5 days at 28 o C, and spread onto new R5-thiostrepton plates. If
the culture continued to grow healthily, and the dark brown secondary metabolites were
observed to be excreted from the mycelia, the culture was amplified over several weeks to
at least 5 liters of culture.

3.4

Extraction of Compounds
Once these plates were confluent with mycelia and brown metabolite, the agar was diced

into small pieces and mashed with a solution of 89% ethyl acetate, 10% methanol, and 1%
acetic acid (v/v) to partition the metabolites from the agar into the solution. The extract
was concentrated by rotary evaporation, purified by HP-20 open column chromatography,
and finally purified by liquid chromatography using an Agilent 1100 chromatograph with a
C-18 Eclipse column and a gradient of 45% acetonitirile and 55% water, supplemented with
0.1% formic acid.
ESI-MS were acquired on an Agilent 6130 LC-MS HPLC (Agilent Zorbax SB-C18
column, 5 m, 21.2 mm 150 mm). 1D and 2D NMR spectra were recorded on a JEOL
instrument (300 MHz).
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CHAPTER 4
Results

4.1

Rabelomycin Pathway Elucidation

4.1.1

Minimal PKS

It had been reported that schP8, schP7, schP6 were the KS, CLF, and ACP, respectively, due to their homology with urdA, urdB, and urdC [5]. The minimal PKS of
urdamycin had already been found to be comparable to jadABC of jadomycin [8] and thus
all of the other minimal PKS clusters that yielded an unreduced polyketide chain of 20
carbons in length. These included the minimal PKSs of actinorhodin (act-ORF1, 2, 3 )
tetracenomycin (tcmKLM ) [22] [29], and oxytetracycline (oxyABC ) [32]. In the absence
of other tailoring enzymes, these enzymes produce a dodecaketide that spontaneously folds
into the molecule known as SEK15 (5) [13,29,32]. We therefore hypothesized that if schP8,
schP7, schP6 were indeed the minimal PKS for 1 and 2, they would work together to
produce what would be observed as (5).

In order to verify this hypothesis, two comparable plasmids were produced, both using
the pRM5 vector as an expression system, depicted in Figure 4.2. One of these was pTZ3,
containing oxyA, oxyB and oxyC immediately after the promoter; the other was pME1,
which had schP6, schP7 and schP8 after the promoter. A list of plasmids can be found in
Table 4.2 below.
When each of these plasmids was transformed into the heterologous host, Streptomyces
lividans K4 via polyethylene glycol-assisted protoplast transformation [20], the resulting
transformants yielded a slightly yellow colored compound that could be seen within the
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schA1

schA3 schA5

schA7

schA2 schA4 schA6

schA11
schA13

schA9

schA8

schA12
schA10

schA15 schA17

schA14

schA16 schA18

schP7
schS6

schS5

schS8

schS10

schS7 schS9

schP3

schA20

schP5

schP9 schP11

schA22

schP1

schA24

schP8 schP10 schA21 schA23

schP4

schS1

schS3

schA26 schA28

schA25

schA27
schA29

schP6

Accessary

schP2 schS2 schS4

schA19

PKS

Deoxysugar

Fig. 4.1: Gene cluster upon which the functions of each step in the biosynthetic pathway
were hypothesized

Fig. 4.2: The vector used to build all of the expression plasmids. Genes were inserted in
between the PacI and NheI restriction sites
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growth medium. Extraction and analysis of both samples resulted in very similar data: a
product peak with [M+H]+ = 359 and [M-H]- = 357 (Figure 4.3 A and B). These data
verify that the product produced by both pME1 and pTZ3 is (5). As such, SchP8, SchP7
and SchP6 were identified as the dedicated ketosynthase, chain length factor and acyl carrier
protein, respectively.

4.1.2

Ketoreductase

We then sought to prove that SchP5 was, as reported, the C-9 ketoreductase. As stated
above, (5) always forms in the absence of such a ketoreductase. However, when a minimal
PKS is expressed with certain C-9 KR genes, various other products form [13].
We were curious how this putative ketoreductase would behave. There were two hypotheses proposed: one, that SchP5 would either act directly on the nascent polyketide
chain, similar to actKR [29]; or two, that it would show up in synthesis later, as seen in the
pdm gene cluster of pradimicin [44]. Thusly, schP5 was introduced to the minimal PKS in
pTZ3 to get pME3 via ligation after oxyC. Transformation of this plasmid into S. lividans
K4 resulted in a slightly darker compound excreted by the cells into the growth medium.
HPLC analysis of pME3 showed a different set of peaks from either of the previous plasmids’ compounds, notably the primary product had an earlier retention time than 5 (4.3
C. ESI-MS spectra revealed that the mass of this product is 386, which is consistent with
the reported RM20 b/c (6) [17].
This result confirms that SchP5 specifically reduces the C-9 keto group of the nascent
chain [13], confirming our first hypothesis that it is very similar to ActKR from the actinorhodin pathway of S. coelicolor A3 [27]. The presence of the ketoreductase allows the
polyketide chain to fold spontaneously into different fused-ring structures, and also allows
the chain to be folded by certain aromatases, which could not utilize it as a substrate were
it not reduced at C-9.
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4.1.3

Aromatases and Cyclases

The next step in the pathway is the formation of the first ring, a procedure typically
catalyzed by an aromatase. In the biosynthetic pathway for 1 and 2, SchP4 is the putative
ARO. This is based on its gene schP4 being 73% homologous to simA5, and 72% homologous to urdL [5], both of which are confirmed first-ring cyclases for simocyclinone in S.
antibioticus [37] and 4 in S. fradiae [11], respectively.

For both simocyclinone and urdamycin A as well as numerous other aromatic polyketide
molecules [3,10,22,23,37], the aromatase is closely related to the subsequent cyclaze; referred
to in a pair as an ARO/CYC. This is because assembly of all other rings is dependent on
the ARO. That is to say, the guided formation of the rest of the molecule is contingent
upon the first ring coming together between C-7 and C-12, whether the molecule is of an
anthracycline formation, an angucycline formation, or neither. Like the ARO, the putative
cyclase SchP9 was identified as such based on its homology with both the urdamycin A
cyclase UrdF and the cyclase of simocyclinone SimA4.
Therefore, to verify the identity of first schP4 and then schP9, the putative ARO was
cloned and inserted after the ketoreductase schP5 in the plasmid pME3, resulting in a
plasmid designated pME4. By expressing oxyABC, schP5 and now schP4 all together, the
resultant molecule would be SEK43 (16), with a molecular weight of 368. Expressing pME4
and comparing its resultant metabolites with that of pME1, pTZ3, and pME3, showed a
comparatively less polar molecule (Figure 4.3 D). ESI-MS of the extract produced molecular
ion peaks of [M+H]+ = 369 and [M-H]- = 367, confirming that the major metabolite of
pME4 was SEK43 (16) and therefore that SchP4 is the dedicated aromatase in the pathway.
Having established the ARO, we proceeded to introduce schP9 to the expression plasmid, which would finish the core structure and result in a recognizable angucycline product.
Ligating schP9 into pME4 after schP4 resulted in the plasmid pME5. When transformed
into S. lividans K4, a compound was produced that was significantly darker than the previous samples had shown. Although it was only detected in trace amounts, the molecule

23
was found to be UWM6 (13), from the ESI-MS that indicated the molecular weight was
342 [22].
We believe that rather than remain with 13 as the major product, the extracted
metabolite mixture would spontaneously oxidize into the structure known as rabelomycin
(14), which has a molecular weight of 338. This was the major peak in the mass spectra of
pME5s products (Figure 4.3 E). Curiously, it was also the major peak of pME6, which is a
plasmid created by adding schP10 to pME5. The enzyme SchP10 is a putative monooxygenase, responsible for catalyzing a carbonyl group forming at C-12. We thus were able to
confirm that SchP10 is indeed the monooxygenase that oxidizes the second ring into the
quinone form. Even without SchP10, rabelomycin can still be produced by oxidation of 13.

4.2

Glycosylation
Many deoxysugars can be made from glucose-1-phosphate [26], a metabolite of glu-

cose. The enzymes responsible for the conversion of glucose-1-phospate to any of several
deoxysugar species seem to be conserved over Streptomyces species. Indeed, the putative
functions of SchS1, 2, 3, 4, 5, and 6 are closest in homology to UrdS, UrdQ, UrdZ3, UrdH,
and UrdG, in that order – all of which are responsible for L-rhodinose and D-olivose synthesis in Urdamycin A [5].
Additionally, the disaccharide moiety attached to C-9 was of particular interest to
us since biologically active molecules with C-linked carbohydrate moieties are better drug
candidates, due to the robustness of the C-glycosidic bond through the harsh pH conditions
of the digestive tract. The putative C-glycosyltransferase of the Sch pathway is listed as
SchS7, with 71% homology to UrdGT2, a confirmed C-glycosyltransferase.
Since it is difficult to verify individually transformed monosaccharides from in vivo
culture, we set out to express the entire putative sugar pathway in a plasmid along with
the rabelomycin scaffold. Furthermore, since UrdGT2 has been reported to be unselective
towards dextrorotary or levorotary deoxysugars [14], we hypothesized that an additional
epimerase, SchS8, might be all that is necessary for completion of the disaccharide attached
to C-9. Based on this reasoning, pKN57, which contained schS2, schS1, schS3, schS8,
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schS7, schS, schS5, schS4 was ligated to pME8 to form pGG31.
GG31 was therefore predicted to be rabelomycin with a D-amicetose moiety attached
via a C-glycosidic bond to carbon 9; with the possibility of an L-amicetose moiety attached
via a (1,4) O-glycosidic bond to the D-amicetose. When transformed into K4, GG31 (17)
was formed, with earlier retention time than 16 (Figure 4.3 F), Ion peaks corresponding
to [M-H]- at m/z 451.1, [M+H]+ at m/z 453.2 in the ESI-MS spectra suggested that the
molecular weight of 17 is 452. 1 H and

13 C

NMR of 17 showed very similar signals to 16,

except one D-amicetose. The structure was suggested as amitosylated rabelomycin, which
was confirmed by plentiful HMBC correlations; these are summarized in Table 4.1, with onedimensional and two-dimensional spectra in Appendix B. The position of the D-amicetose
attachment was also at C-9 based on the HMBC correlations from H-1’ to C-8, 9, 10 and
from H-10 to C-1’ (Figure 4.5). The stereostructure was proposed the same as 16.

4.3

Angular Hydroxyls
Since both 1 and 2 have two hydroxyl groups at C-4a and C-12b, but neither 13 nor

17 do, it was apparent that the oxidoreductase responsible for these groups was neither
SchP9 nor SchP10. Indeed, the enzymes responsible for catalysis of the hydroxyl formation
at the angle are being investigated in many different angucycline biosynthetic pathways
[15, 18, 19, 31]. The two hypotheses for any given angucyclic natural products are that
there is one dioxygenase that results in formation of both C-4a and C-12b hydroxyls; or a
monooxygenase that yields an epoxide intermediate before being opened by a water attack
[38].
In the pathway of 1 and 2, there are six putative oxygenases: SchA18, SchA19, SchP3,
SchP10, SchA24, and SchA26. Having identified SchP10 as the C-12 oxygenase and SchA26
as very likely responsible for reduction of side-chain deoxysugar moieties [2,5], four are left.
SchP3 is homologous with UrdM of S. fradiae, and has been evaluated as responsible for
the catalysis of both C-4a and C-12b hydroxyls (see Figure 2.4 in the Literature Review).
By ligating schP3 into pGG31 after the last sugar synthase gene schS4, we created the
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Table 4.1:
1H

(300 MHz) and

13 C

(75 MHz) NMR summary for GG31 in acetone-d 6 ;
(δ in ppm, J in Hz)

No.

δC

δH

1

156.3

2

121.6

3

142.0

4

120.2

4a

139.3

5

121.4

8.15 (d, 1H, 7.6)

6

121.6

8.31 (d, 1H, 7.6)

6a

135.2

7

188.5

7a

115.9

8

159.4

9

139.4

10

133.6

7.89 (d, 1H, 7.2)

11

121.4

7.87 (d, 1H, 7.2)

11a

133.1

12

189.7

12a

132.7

12b

122.0

13

21.4

2.49 (s, 3H)

1’

73.3

4.85 (d, 1H, 9.4)

2’

32.0

1.50 (m, 1H); 2.28 (m, 1H)

3’

33.3

1.73 (m, 1H); 2.25 (m, 1H)

4’

79.0

3.46 (m, 1H)

5’

72.3

3.40 (m, 1H)

6’

14.1

1.40 (d, 1H, 5.8)

7.16 (s, 1H)

7.26 (s, 1H)
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Table 4.2: Plasmid construction
Plasmid

Genes

Major Product

pTZ3

oxyA, oxyB, oxyC

SEK15

pME1

schP6, schP7, schP8

SEK15

pME3

schP6, schP7, schP8, schP5

pME4

schP6, schP7, schP8, schP4, schP5

SEK43

pME5

schP6, schP7, schP8, schP4, schP5, schP6

UWM6

pME6

oxyA, oxyB, oxyC, schP4, schP5, schP9, schP10

Rabelomycin

pME8

schP4, schP5, schP6, schP7, schP8, schP9,

Rabelomycin

RM20 b/c

schP10
pKN57

schS1, schS2, schS3, schS4, schS5, schS6, schS7,

Amicetose and transfer

schS8
pGG31

schP6, schP7, schP8, schP4, schP5, schP9,

GG31

schP10, schS1, schS2, schS3, schS4, schS5, schS6,
schS7, schS8
pGG53

schP6, schP7, schP8, schP4, schP5, schP9,

GG53

schP10, schP3

plasmid pGG53. When analyzed, the major product had a retention time less than that
of 17. The ESI-MS spectrum depicted [M+H]+ at m/z equal to 355; [M-H]- at m/z equal
to 353, indicating a molecular weight of 354 (see Figure 4.6). This compound was dubbed
GG53, and is hypothesized to have a structure similar to the molecule indicated as 18,
although stereochemical correlations have not yet been found to verify this.
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Fig. 4.3: HPLC comparison of products from expression plasmids transformed into S. lividans K4. A: pTZ3; B: pME1; C: pME3; D: pME4; E: pME5; F: pGG31
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Fig. 4.4: Structures of urdamycin A and simocyclinone D8, which have ARO/CYC homologous to those in the Sch pathway

Fig. 4.5: Structure elucidation of GG31
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Fig. 4.6: Comparison of retention times of GG53 (18), which is more polar than rabelomycin
(16), and LC-MS spectra
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Fig. 4.7: Proposed pathway to 1 and 2
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CHAPTER 5
Conclusions
In the search for novel bioactive compounds, we produced two compounds, 15 and 16
using combinatorial biosynthesis. We believe that these “unnatural” natural products are
intermediates in the pathway to compounds 1 and 2, the natural secondary metabolites
of Streptomyces sp. 2136. These two products signify the promise of engineering novel
compounds via metabolic pathway recombination. The original compounds 1 and 2 have
shown promising antifungal activity for many different species, and potential anticancer
activity via inhibition of tryptophan 5-monooxygenase and tyrosine hydrolase. Moreover,
by expressing these and other type II polyketide synthase genes together, new molecules
can be made without the environmental costs of chemical synthesis.
We first confirmed that the minimal PKS of the sch gene cluster was SchP8, SchP7,
and SchP6. This minimal PKS is able to produce the same well-known compounds as
several other minimal PKSs from various Streptomyces species: SEK15 (5 and RM20b/c
6). Therefore, these genes synthesize a 20-carbon polyketide chain that will be shaped into
the polyaromatic backbone of the natural products 1 and 2. A summary of all the gene
functions is listed below in Table 5.1.
We also verified the functions of the other SchP enzymes, SchP4 through SchP10, as
crucial enzymes in the synthesis of rabelomycin (14), another intermediate in the pathway
to the biosynthesis of 1 and 2. Of these, SchP4 is the aromatase (ARO), SchP5 is the
ketoreductase (KR), SchP9 is the cyclase (CYC), and SchP10 is an oxygenase (OX). Not
only were the functions confirmed, but the sequence specificity of many of the enzymes were
also resolved. (For example, the selectivity of SchP5 to work on the nascent polyketide
chain, instead of working on the structure later in the synthesis.) Additionally, the minimal
PKS genes from the oxytetracycline pathway oxyA, oxyB and oxyC can be exchanged with
schP6, 7, and 8, suggesting a broader conclusion that the Type II PKS pathway of ATCC
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55186 shares many similarities with other type II PKS pathways.
We were also able to confirm the functions of the sugar synthase enzymes SchS1 through
SchS6, which have very similar functions to other sugar synthases. Together, these enzymes
work to first synthesize the deoxysugar D-amicetose, and then the C-glycosyltransferase
SchS7 attaches the sugar onto the rabelomycin backbone at the C-9 position. As noted, the
attachment of the sugar to C-9 was expected, but ongoing experiments are being performed
to test the substrate selectivity of SchS7 for both deoxysugar and aglycan specificity.
Table 5.1: Gene functions
Gene

Function

schP6

Acyl Carrier Protein

schP7

Chain Length Factor

schP8

Ketoacyl synthase

schP5

C-9 ketoreductase

schP4

Aromatase

schP9

Cyclase

schP10

C-12 oxygenase

schS7

C-glycosyltransferase

schS1

Hexose 3-ketoreductase

schS2

Hexose 3-ketoreductase

schS3

Hexose 3-dehydratase

schS4

Hexose 4-ketoreductase

schS5

Hexose 4,6-dehydratase

schS6

Hexose NDP-glucosynthase

A few steps still remain before we have the full pathway to 1 and 2, however. We are
still pursuing the synthesis and attachment of the other sugars, L-amicetose and aculose,
because other studies have shown that the full complement of deoxysugars is crucial to
compounds biological activity [1, 40].
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In addition, the gene cluster contains many other proteins with unknown functions that
we remain curious about. Perhaps some of them synthesize a different secondary metabolite
under other conditions; perhaps they modify 1 and 2 or assist in the emission from the cell.
There is strong functional homology between several organisms biosynthetic machinery, so
the answers to these questions may be within reach.
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CHAPTER 6
Future Work

6.1

Glycodiversification
The second sugar in the disaccharide connected to C-9 is L-amicetose in Sch-47554, and

is aculose in Sch-47555. The pathway for the synthesis of these two different deoxysugars
is proposed in Figure 6.1, and is potentially just a different branch off of the pathway from
glucose-6-phosphate to amicetose.

Fig. 6.1: Putative route from glucose-6-phosphate to the three sugars. We have confirmed
the pathway to D-amicetose
With this hypothesis, the only genes that need to be included in an expression plasmid are schA26, a nucleotide that codes for an oxidoreductase with homology to AknOx
from the aclacinomycin biosynthetic pathway of S. galilaeus [2]; and the appropriate Oglycosyltransferase, either SchS9 or SchS10. Knockout studies are currently being done by
other members of our laboratory to determine in the full pathway which of the glycosyltransferase enzymes is responsible for each of the O-glycosidic bonds.
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Additionally, some exploration has been done towards the coupling of different sugars
onto angucyclic or tetracyclic scaffolds. One of these is olivose, which was discussed in the
Literature Review as being attached to Urdamycin A at C-9 by UrdGT2; but other studies
have shown that UrdGT2 is able to catalyze the transfer of different sugars [14]. In this way,
the library of Sch-like antifungal compounds can grow, lending insight into the usefulness
of the deoxysugars to mitigate infections.

6.2

Co-expression of Two Plasmids to Assist with Combinatorial Biosynthesis
All of the heterologously expressed compounds discussed in this thesis were expressed

by transforming a single expression plasmid with the required polyketide synthase genes into
S. lividans K4. The vector used was derived from the plasmid pRM5 [27] that itself was
constructed from the SCP2* self-replicating plasmid found in S. coelicolor. pRM5 allows for
easy ligation of a block of genes between the PacI and NheI, or PacI and EcoRI restriction
sites (see Figure 4.2 in the Results section). The smallest of the expression plasmids used
was pME1, which expressed 5, of size 18.8 kilobase pairs in length. The largest is pGG31,
which is a 31.5 kilobase pairs in length.
Further adding individual genes is tedious at best, due to the increasing size of the
plasmid. Direct insertion of the new gene into a single-cut, e.g., NheI, of such an expression
plasmid is extremely improbable; and verification of correct ligation proves to be difficult
and time-consuming. Thus, instead of growing an existing plasmid from upwards of 32,000
base pairs by adding more nucleotides, the best possible procedure is to add the new genes
to a plasmid with different antibiotic resistance, and co-transform the two plasmids into the
Streptomyces protoplasts.
A few attempts at such co-transformation were made, but yielded the same results
as the control: the second plasmid was never seen to express. This could be due to the
use of pSET152 [28] as the co-expression plasmid. While it has suitable restriction sites
for cloning as well as a suitably different antibiotic resistance gene (apramycin), pSET152
was originally created to be integrative rather than self-replicating, thus the efficiency of
gene transcription and translation is lower. Additionally, because of its original integrative
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purpose, pSET152 lacks a promoter. This was remedied by others in our lab via the inclusion
of the erythromycin promoter from Saccharopolyspora erythraea [39], but their studies only
utilized it to express a single gene; the ideal co-expression vector would have the capability
to express several nucleotides.
In fact, the ideal co-expression vector would be identical to pRM5, with the exception
of the antibiotic resistance gene. A suitable resistance gene would provide selection for an
antibiotic other than thiostrepton; the two historic choices seem to be apramycin (aac(3)
IV ) or hygromycin (hyg) [28], both of which are aminoglycosides that disrupt protein
synthesis. Some candidates include p6perme or pRLE6 [12]. Conversely, it is possible that
the vector might have to be engineered from a commercial vector like pJET or pUC19, and
have the desired promoter, replicon, and restriction sites placed in optimal positions. The
fact remains that co-expression is very likely the key to novel natural product biosynthesis.
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Table A.1: Numbered Compounds in this Thesis
№

Name

Formula

1

Sch 47554

C37H38O13

2

Sch 47555

C37H42O13

3

Aquayamycin

C25H26O10

4

Urdamycin A

C43H56O17

5

SEK15

C20H16O8

6

RM20 b/c

C20H18O8

7

SEK4

C18H18O5

8

Mutacin

C16H18O6

9

WJ85

C19H13NO7

Structure
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№

Name

Formula

10

WJ35

C19H17NO8

11

Anhydrotetracycline

C22H22N2O7

12

Oxytetracyline

C22H24N2O9

13

UWM6

C19H18O7

14

Rabelomycin

C19H14O6

15

Urdamycin L

C19H14O7

16

SEK43

C20H16O7

17

GG31

C26H26O7

18

GG53

C19H14O7

Structure
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Appendix B
Nuclear Magnetic Resonance Spectra for Structure Confirmation of GG31
As stated previously in the Experimental section, the nuclear magnetic resonance spectrophotometer used for characterization of molecules in this study was a JEOL ECX-300
instrument. I wish to specially acknowledge Dr. Tong Zhou for his assistance.

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

